Skip to main content

Official Journal of the Italian Society of Orthopaedics and Traumatology

Table 3 Outcomes at 52 weeks

From: Clinical and radiographic comparison of a single LP-PRP injection, a single hyaluronic acid injection and daily NSAID administration with a 52-week follow-up: a randomized controlled trial

 

PRP

HA

NSAID

P

Patients

33

32

33

 

Responders [no. (%)]

 20% decrease WOMAC pain

10 (30)

0

0

< 0.001

 20% decrease WOMAC stiffness

9 (27)

0

0

< 0.001

 20% decrease WOMAC physical function

8 (24)

0

0

< 0.05

 20% decrease VAS

5 (15)

0

2(6)

< 0.001

Change from baseline

 WOMAC pain

  % change from baseline

− 20.39

− 1.03

− 6.4

< 0.03

  End of follow-up

4.84 ± 0.7

5.96 ± 0.4

5.72 ± 0.45

< 0.001

 WOMAC stiffness

  % change from baseline

− 16.1

− 0.7

4.9

< 0.001

  End of follow-up

3.45 ± 0.5

4.03 ± 0.3

4.27 ± 0.45

< 0.002

 WOMAC physical function

  % change from baseline

− 19

0.3

0.9

< 0.001

  End of follow-up

26.21 ± 0.8

32.65 ± 0.7

32.78 ± 0.73

< 0.05

 WOMAC total

  % change from baseline

− 18.9

0.07

0.2

< 0.001

  End of follow-up

34.51 ± 1.2

42.65 ± 0.9

42.78 ± 1.02

< 0.02

 VAS

  % change from baseline

− 18.2

3

− 6.4

< 0.001

  End of follow-up

5.03 ± 1.7

6.25 ± 0.4

5.75 ± 0.43

< 0.001

  1. A primary response was defined as the percentage of patients having a 20% decrease in the summed score for the WOMAC pain. Quantitative variables are expressed as mean standard deviation. P < 0.05 is considered statistically significant